GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Class II and III) to improve exercise capacity.

Ambrisentan is an endothelin receptor antagonist that blocks the endothelin A receptor on vascular smooth muscle cells and cardiac myocytes, preventing vasoconstriction and smooth muscle cell proliferation.

The recommended dose of Volibris is 5mg once daily. Some additional efficacy has been observed with 10mg once daily in patients with class III symptoms, however an increase in peripheral oedema has also been observed.

Patients with associated connective tissue disease may require 10mg once daily.

Volibris is currently the only drug licensed for patients with class II pulmonary arterial hypertension.

View Volibris drug record

Further information: GlaxoSmithKline

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases